As of Mar 27
| +0.08 / +1.27%|
The 8 analysts offering 12-month price forecasts for Endocyte Inc have a median target of 9.50, with a high estimate of 21.00 and a low estimate of 6.00. The median estimate represents a +49.37% increase from the last price of 6.36.
The current consensus among 9 polled investment analysts is to Buy stock in Endocyte Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.